Susquehanna International Group, LLP Puma Biotechnology, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 12,600 shares of PBYI stock, worth $38,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,600

Previous 256,263 95.08%

Holding current value

$38,052

Previous $835,000 96.17%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$2.92 - $5.83 $369,134 - $737,005	-126,416 Reduced 33.03%	256,263 $835,000
Q1 2024 May 07, 2024	BUY	$4.29 - $7.4 $1.01 Million - $1.74 Million	235,121 Added 159.34%	382,679 $2.03 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $110,465 - $222,416	49,536 Added 50.54%	147,558 $638,000
Q3 2023 Nov 14, 2023	SELL	$2.63 - $4.09 $6,806 - $10,584	-2,588 Reduced 2.57%	98,022 $257,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $940,123 - $1.29 Million	-361,586 Reduced 78.23%	100,610 $355,000
Q1 2023 May 16, 2023	BUY	$2.21 - $4.82 $448,157 - $977,428	202,786 Added 78.17%	462,196 $1.43 Million
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $244,828 - $586,663	115,485 Added 80.24%	259,410 $1.1 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $53,347 - $90,243	23,501 Added 19.52%	143,925 $341,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $97,912 - $197,019	59,703 Added 98.32%	120,424 $343,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $357,222 - $543,380	-167,710 Reduced 73.42%	60,721 $175,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $507,225 - $1.17 Million	177,974 Added 352.72%	228,431 $694,000
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $45,780 - $64,837	-6,905 Reduced 12.04%	50,457 $354,000
Q2 2021 Aug 11, 2021	BUY	$8.98 - $11.6 $117,269 - $151,484	13,059 Added 29.48%	57,362 $527,000
Q1 2021 May 17, 2021	SELL	$9.38 - $13.63 $583,858 - $848,399	-62,245 Reduced 58.42%	44,303 $431,000
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $195,596 - $304,960	25,141 Added 30.88%	106,548 $1.09 Million
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $98,192 - $115,143	-10,336 Reduced 11.27%	81,407 $821,000
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $680,110 - $1.28 Million	-97,020 Reduced 51.4%	91,743 $957,000
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $516,894 - $1.2 Million	-82,308 Reduced 30.36%	188,763 $1.59 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $263,133 - $434,371	40,482 Added 17.56%	271,071 $2.37 Million
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $255,535 - $375,271	29,204 Added 14.5%	230,589 $2.48 Million
Q2 2019 Aug 16, 2019	BUY	$12.3 - $35.76 $131,659 - $382,775	10,704 Added 5.61%	201,385 $2.56 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $933,951 - $2.72 Million	75,931 Added 66.17%	190,681 $2.42 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $184,312 - $375,991	8,874 Added 8.38%	114,750 $4.45 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $2.3 Million - $5.34 Million	-114,441 Reduced 51.94%	105,876 $2.16 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $8.89 Million - $12.9 Million	-215,837 Reduced 49.49%	220,317 $10.1 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $9.18 Million - $13 Million	189,962 Added 77.16%	436,154 $25.8 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $857,948 - $1.43 Million	14,371 Added 6.2%	246,192 $16.8 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $12.8 Million - $18.1 Million	136,599 Added 143.45%	231,821 $22.9 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $6.86 Million - $11.4 Million	95,222	95,222 $11.4 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $138M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Puma Biotechnology, Inc. Transaction History